Redeye comments on the now confirmed partnering with industry giant Quest Diagnostics for channel co...
Alzinova is a Sweden-based clinical-stage biopharmaceutical company seeking to advance treatments fo...
Redeye comments on Jumpgate’s Q2 report, which was broadly in line with our estimates, with the exce...
Redeye comments on Nekkar’s Q2 report, that presented mixed Q2 figures during a relatively slow peri...
Redeye comments on Fable Media Group’s Q2 results, aligning with the preliminary figures and our est...
Train Alliance levererade ett starkt andra kvartal med stigande intäkter och en förbättrad rörelsema...
Redeye comments on GiG’s Q2-results which were in line with expectations and the preliminary outcome...
Nanexa presented strong validation of its PharmaShell technology during the first half of 2025, with...
Redeye provides an in-depth review of AcouSort’s Q2 report and activities during and after the quart...
Redeye is impressed by the strong delivery from GomSpace during the last two quarters, posting stell...
Redeye initiates coverage of BICO, a leading player in the bioconvergence space.
Redeye makes a correction to our estimates, slightly impacting our fair value range.
* Enedo drove the 6% Q2 adj. EBITA miss while Inission beat by 4% * 1.
* Europe and other markets continue to perform, North America less so * We reset our expectations-po...
Q2-rapporten överraskade positivt med stark orderingång och förbättrad lönsamhet, även om nettoomsät...
Atria plans EUR 16m investment in its Kauhajoki plant to modernise production and reorganise beef pr...
Redeye comments on the Q2 report. Top-line figures came in broadly in line with our expectations.
Nettoomsättningen för det andra kvartalet 2025 uppgick till 142,1 MSEK (114,2), motsvarande en organ...
New Wave Groups Q2-rapport var svagare än väntat med lägre omsättning och resultat, främst tyngt av ...
Oncopeptides (ONCO) is a Swedish biotech that aims to develop and commercialise therapies for diffic...
